After Novartis left, Boehringer bets up to $500M on the field of prescription smartphone apps
Boehringer Ingelheim wants in on digital therapeutics.
The German pharma signed an up to $500 million collaboration with Click Therapeutics, one of a handful of major companies developing prescription computer and smartphone applications for various neurological or mental disorders. They join a small list of pharmas that have decided to test the waters in the emerging field.
Under the deal, Boehringer and Click will co-develop a digital therapeutic for schizophrenia, known as CT-155. It’s a complementary effort to Boehringer’s more traditional schizophrenia work. The company has concentrated their neuroscience efforts there since 2018, when a Phase II failure blew up their late-stage Alzheimer’s efforts.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.